Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential

Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR chromatin binding profiles are highly plastic and form recurrent programmatic changes that differentiate disease stages, subtypes and patient outcomes. While prior studies focused on concordance between patient subgroups, inter-tumor heterogeneity of AR enhancer selectivity remains unexplored. Here we report high levels of AR chromatin binding heterogeneity in human primary prostate tumors, that overlap with heterogeneity observed in healthy prostate epithelium. Such heterogeneity has functional consequences, as somatic mutations converge on commonly-shared AR sites in primary over metastatic tissues. In contrast, less-frequently shared AR sites associate strongly with AR-driven gene expression, while such heterogeneous AR enhancer usage also distinguishes patients’ outcome. These findings indicate that epigenetic heterogeneity in primary disease is directly informative for risk of biochemical relapse. Cumulatively, our results illustrate a high level of AR enhancer heterogeneity in primary PCa driving differential expression and clinical impact.

Androgen receptor usage is heterogeneous in primary prostate cancer patients
Prostate cancer (PCa) has the second highest incidence in men worldwide and depends on androgen receptor (AR) signaling to drive proliferation. As a hormone-driven transcription factor, chromatin binding is a critical component of AR action, and genomic binding selectivity directly impacts AR-controlled gene expression repertoires. Recently, we reported an integrative epigenetic taxonomy of primary PCa tissues using RNA-seq coupled with ChIP-seq of histone post-translational modifications and AR, yielding a total universe of 69,330 AR binding sites (ARBS) found in 88 prostate tissues. Our work revealed three distinct epigenetics-based PCa subtypes, differentiating tumors by oncogenic drivers and transcriptional programs. Other studies revealed robust programmatic plasticity in AR enhancer action during tumor development, metastasis formation, and treatment resistance, while remaining largely similar between different
metastatic lesions from the same patient. Cumulatively, these reports provide evidence for PCa progression through robust, reproducible, and programmatic epigenetic reprogramming.2–7

In this work, we investigate the extent and consequences of inter-tumor heterogeneity in AR chromatin binding using our aforementioned ARBS universe.3 We identify a high level of AR chromatin binding heterogeneity between different primary PCa samples, with <5% of all AR binding sites (ARBS) shared by half of the tumors analyzed, which rigorous QC analyses support. Through computational integration of clinical data and a rich spectrum of PCa genomic datasets,2,8–10, including somatic mutation data from 200 primary10 and 101 metastatic PCa tumors,11, functional AR enhancer activity mapping of 20,790 ARBS through massive parallel reporter assays,12, enhancer CRISPR screening,13 single-cell chromatin accessibility sequencing data from PCa cells14 and 3D-genome data,15 we deeply characterize the biological basis and consequences of AR enhancer heterogeneity in PCa and assess its clinical impact on patient metastatic progression.

**Results**

**AR enhancer usage is highly heterogeneous in primary PCa**

Previously, we reported a total universe of 69,330 ARBS in a cohort of 88 primary prostate cancers with >80% tumor cell percentage, averaging 2,394 peaks per tumor with FRIP scores >1.5 (Supplementary Tables 2–4), which were processed in a standardized manner minimizing cell death and optimizing sample quality (see the “Methods” section). To annotate inter-tumor heterogeneity of enhancer usage, we ranked ARBS based on detected peaks in the fraction of tumors analyzed, revealing an unexpected high level of AR enhancer heterogeneity between tumors (Fig. 1a), with typical AR-inducible genes FKBPS and KLK3 regulated by highly ranked ARBS enhancers 129 and 343 (enhID, Source Data), respectively. Based on ARBS prevalence in patients, we binned these ARBS in three categories: shared (SH; in AR sites identified in 68% or more of the patients), partially shared (PS; AR sites found in 2–67% or more of the patients) and unique peaks (UN; AR peaks observed in merely one patient).

To which degree does AR binding in frequently-used PCa cell lines represent the enhancer heterogeneity found in tumors? We overlapped AR ChiP-seq data from treatment sensitive16–18 and resistant2–7 PCa cell lines with all ranked ARBS, displaying enrichment of commonly shared ARBS for all tested PCa cell lines and AR-transduced normal prostate LSHAR cells. However, as a control for prostate selectivity, we observe that overlap of ARBS from PCa was largely absent in monocytic THP-1 cells19 and molecular apocrine ER+/AR− MDA-MD4135 breast cancer cells (Fig. 1b, c, Supplementary Table 5). Of note, we observe a further shift towards SH-ARBS enrichment in the acquisition of therapy resistance for both bicalutamide-resistant LNCaPBR and enzalutamide-resistant LNCaP derivative 42DENZR. In normal epithelial prostate tissues (n = 15), we observed a highly similar heterogeneous ARBS ranking (n = 27,850, Fig. 1b, Supplementary Fig. 1A). Tumor and normal ranked ARBS rankings follow strikingly similar distributions considering the genetic heterogeneity of tumors2–7, suggesting that AR enhancer heterogeneity is not tumor-intrinsic, but instead patient-intrinsic (Fig. 1d, Supplementary Fig. 1G), corroborating our previous case-study investigating high intermetastatic AR binding overlap from the same patient.2

As ChiP-seq data quality and peak calling can be impacted by technical limitations,2,6 we performed extensive quality control analyses (NSC, RSC, FRIP, GC%, MSPC, and single mapped reads/AR ChiP-seq read correlation tests, Supplementary Figs. 1, 2) to test whether the observed inter-tumor AR heterogeneity results from technical artifacts. Samples contained comparable high fractions of tumor cells (Supplementary Table 2) and although total ARBS identified per sample fluctuated, AR expression levels for each sample did not correlate with the total number of AR ChiP-seq peaks, nor did read depth (RD) correlate with the total AR ChIP-seq peaks per sample, indicating biological variation between samples as opposed to technical variation (Supplementary Table 3, Supplementary Fig. 1E, F).

Strong ChiP-seq signals were found at SH-ARBS, while such signal on the individual patient level was weaker or absent at PS-ARBS. Interestingly, we identify UN-ARBS with clearly distinguishable signal from the background and of generally comparable intensity as PS-ARBS, showing that peak calling correctly identified UN-ARBS (emplified in Fig. 1e, aggregate peaks quantified in Fig. 1f). Moreover, we detected occurrence of UN-ARBS in PCa cell lines (Fig. 1b) and alternative multiple sample peak calling (MSPC, see the “Methods” section) of ranked ARBS with multiple testing correction confirmed heterogeneous peaks as highly significant true-positives with comparable GC content, ARBS peak distribution and specific UN-ARBS signal over background (Supplementary Fig. 1B, C, E, H). Samples with low RD according to ENCODE4 Transcription Factor (TF) ChiP-seq standards had similar UN-ARBS and AR motif score distributions as those coming from samples with high RD (Supplementary Fig. 2). Moreover, no correlation was observed between samples with different RD quality categories and FRIP, NSC or RSC metrics (Supplementary Fig. 2A, C). Finally, UN-ARBS in quality outlier sample P349T did not contribute significantly to overall analyses (Supplementary Fig. 1E and Supplementary Fig. 2F, G).

As expected and previously reported14,21, ~80% of ARBS are present in introns or intergenic regions that are generally considered putative enhancers with cis-regulatory potential22 (Fig. 1g, Supplementary Fig. 1D). Interestingly, genomic distributions of ARBS were not equally distributed over consensus, with higher promoter enrichment in more heterogeneous occupied ARBS. Moreover, in all three ARBS categories, we found motifs for AR as well as canonical AR-interactors FOXA123 and HOXB134 (Fig. 1h, i, Supplementary Fig. 2H). Additionally, distributions of AR motif scores detected in UN-ARBS using MISP motif screen were equal for RD categories (Supplementary Fig. 2I). We tested our ARBS universe for significant overlaps in GIGGLE24 (see the “Methods” section), which analyses over 14,000 individual ChiP-seq databases for TF binding overlap, and confirmed binding of these classical prostate lineage TFs for SH- and PS-ARBS (Supplementary Fig. 1H). Cumulatively, these data support genuine enrichment of heterogeneous ARBS in sequencing analysis, with co-enrichment of TFs associated with canonical AR action. Interestingly, MED1 and RNA Polymerase II subunits, but not AR nor its classical interactors, were enriched in UN-ARBS in GIGGLE (Supplementary Fig. 1H). Like PS-ARBS, UN-ARBS are mostly associated with active TSS and enhancers (Supplementary Fig. 1J), whereas this analysis was uninformative for SH-ARBS due to the relatively small group size (n = 1201). Taken together, these GIGGLE analyses indicate occupancy by functional enhancer-binding proteins on patient-unique ARBS and stress their context-dependent nature.

**Ranked ARBS have functional divergence on enhancer activity and mutation frequency**

We tested ranked ARBS for bona fide enhancer activity and hormone dependency using available data from a massive parallel reporter assay testing enhancer potential for 7422 ARBS in LNCaP25 in vehicle versus DHT conditions (Fig. 2a), resulting in ARB’s enhancer potential that could be classified as inactive, inducible or constitutively active. Most-commonly shared ARBS were enriched for hormone-dependent enhancer activity (n = 286), relative to constitutively activate (n = 463) or inactive sites (n = 2467), suggesting hierarchical functional consequences of ARBS heterogeneity (Fig. 2b, c). The total set of 7422 ARBS analyzed in STARR-seq was expanded to 20,790 regions using a machine learning-based ARBS annotation, confirming our original conclusions with a more complete representation of total ARBS heterogeneity (Fig. 2b, c). To confirm these results, we performed additional STARR-seq targeted at 2495 randomly sampled heterogeneous
ARBS to validate predictions of heterogeneous enhancer activity and confirmed the presence of active enhancers in heterogeneous ARBS, suggesting that a subset of these ARBS function as enhancers (Fig. 2b, c, Supplementary Fig. 3A, B). Finally, individual ARBS activity was validated for a subset of regions represented in the STARR-seq library for each element designation (inducible, constitutive and inactive) through luciferase assays, which confirmed their previously identified activity status and hormonal dependency (Supplementary Fig. 3C, D, Supplementary Table 6).

Having established an association of AR enhancer heterogeneity in PCa with biological consequences on enhancer activity, we next investigated the impact of 764 risk single nucleotide polymorphisms (rSNPs) and single nucleotide variation (SNV) reported previously in primary PCa \((n = 278,209)\) and in metastatic PCa (mPCa,
n = 1,048,576) on primary ranked ARBS as SNVs accumulate during PCa progression. Moreover, we included germline allelic imbalance SNP data (cQTL, n = 4454; q < 0.05) which was called from our primary AR ChIP-seq data in a recent Cistrome-Wide Association Study (CWAS)29. Overlap of rSNPs with primary ranked ARBS was limited (52 out of 764 unique rSNPs) without any enrichment on particular ARBS, while germline cQTL SNPs and somatically acquired SNVs in primary and metastatic PCa are enriched in primary SH-ARBS (n = 1201, Fig. 2d, e), and these sites were previously associated with AR occupancy. Highly active transcribed regions are characterized by high levels of clustered H3K27 acetylation regions, referred to as ‘super-enhancers’31–34, and describe tissue-specific-binding profiles that are typically AR-positive in PCa cell lines and tissue. These super-enhancers encompass ARBS found throughout ranked ARBS (Fig. 2f), as exemplified by recently reported VCaP SEs at PCAT1/2 regulating MYC expression during CRPC35, which is constituted by PS- and UN-ARBS that are affected by rSNPs and SNVs (Fig. 2g). Collectively these data show that ranked ARBS expose hierarchical enhancer activity, and display enrichment of primary and metastatic SNVs in SH-ARBS. Contrarily, super-enhancers are found scattered throughout the ARBS ranking, suggesting that PS- and UN-ARBS can functionally drive oncogenic processes.

Enhancer-specific copy number alterations at heterogeneous ARBS drive transcriptional output in metastatic disease

Next to SNVs, large structural events like copy number alterations (CNAs) are frequently observed in mPCA as drivers of progression11,34. In metastatic disease, CNAs of enhancers with tumor-driving potential for AR11,31, FOXA136, and HOXB1337 have been reported. A previously reported large sequencing database of 101 mPCa tissues38 reported that 23 mPCa patients had known CNA gains at exclusively the AR enhancer locus, of which PS- and UN-ARBS were previously identified as tumor-associated17 and metastatic-associated18 ARBS (Fig. 3a, Supplementary Table 7, Source Data). We reconfirmed previously reported promoter–enhancer interactions by integrating ranked ARBS using H3K27ac HiChIP data38. Numerous ARBS are in close proximity to a single promoter in 3D genome space, confirming previously reported VCaP AR ChIA-PET data39. For example, we identify chromatin loops between PS- and UN-ARBS and the AR promoter (Fig. 3a). As expected, large CNA gains and losses in mPCa patients40 affect ARBS with enhancer–promoter interaction irrespective of ranking, including PS- and UN-ARBS, that potentially affect the expression of tumor-driving genes (Fig. 3b, Supplementary Fig. 4). Moreover, we observe a multitude of structural variations (SVs) in these sites, most notably deletions, inversions or tandem duplications at well-described PCa SV loci like tumor suppressors SPOPL at chr2q and DCC/BCL2 at chr8q (Fig. 3b).

To globally assess tumor-driving enhancer amplifications and losses, we used the cancer gene dependency repository (DepMap)41 and investigated whether CNA-affected ARBS interact with gene loci regulating essential genes in PCa cell lines (VCaP, 22Rv1, and LNCaP, Supplementary Table 8). Based on these analyses, we found 25 essential genes interacting with CNA-affected ARBS, including previously described PCa drivers AR11,13, GRHL240, and HOXB13 (Fig. 3c). These genes interact with PS- and UN-ARBS with a majority of ARBS found in <20 patients (Fig. 3d). Importantly, CNAs at exclusively these ARBS frequently altered corresponding mPCa gene expression42 to a comparable extent as CNAs at exclusively gene coding sequences (Fig. 3e), as was evident for AR-upregulated (AR and ZBTB10) and AR-downregulated (ID1, CITED2, and BCCIP) genes. These findings underline how mPCa CNA-affected ARBS are only found in a minority of primary PCa tissues, which later during mPCA have transcriptional consequences for critical PCa tumor-driving genes.

Transcriptional variation is associated with less-commonly shared ARBS

We predicted which ARBS influence gene expression most in our cohort by modeling H3K27ac-based HiChIP interacting ARBS–promoter pairs and matched gene expression from 88 primary patients in a generalized linear model (GLM), which generalizes linear regression of ARBS occupancy in patients to their transcriptional response. For example, the complete ARBS landscape of CITED2 (PCa tumor-driving gene, Fig. 3e) has a high degree of ARBS heterogeneity including many PS- and UN-ARBS scattered between individual tumors on Chr6 (Fig. 4a).

The CITED2 GLM shows that an ARBS found in 54 primary tumors, and not the most-commonly shared site found in 80 tumors, was most significantly associated with gene expression differences (Fig. 4b), with model assumptions such as linearity of points and limited individual point influence holding (Supplementary Fig. 5A). Additionally, as expected from trends observed in genome-wide AR ChIP-seq peak strengths in the three ARBS categories (Supplementary Fig. 1E, F), we find a clear negative correlation between ChIP-seq peak strength and ARBS category across all ARBS and patients (Supplementary Fig. 5B, C). In total, 2026 ARBS regaining 1901 unique genes were identified by GLMs to significantly associate genome-wide AR ChIP-seq with expression differences (p < 0.001).

As these observations are from bulk measurements, single-cell assay for transposable-accessible chromatin sequencing (scATAC-seq) from LNCaP43 was used to infer promoter–enhancer interactions and ARBS accessibility throughout cell cycle phases. Although few ARBS were cell-cycle phase-specific in arrested bulk LNCaP43 and AR activity fluctuates among scATAC-seq clusters, there is an enrichment of ranked ARBS and de novo AR and FOXA1 motifs in differentially accessible chromatin (Supplementary Fig. 6). Links are observed between most heterogeneously bound ARBS and the CITED2 promoter in LNCaP (Fig. 4c), in agreement with LNCaP H3K27ac HiChIP data3.

Subsequently, for CITED2 we assessed which proximal ARBS have a functional impact on transcriptional output. For this, we genetically
deleted the entire ARBS through CRISPR-Cas9-mediated genome editing by transducing LNCaP with Cas9 and confirming its activity in a polyclonal population (Supplementary Fig. 7A, B), designing guide pairs and combining these in pools to maximize the chance of a KO in case of a non-effective single guide. Guide pairs and pools were targeted to ARBS edges identified with scATAC-seq, which had AR binding in LNCaP (Fig. 4d) and we confirmed successful Cas9 deletion through genomic DNA PCR. We observed a concomitant drop in CITED2 expression for the CITED2 enhancer found in 54 primary tumors (CI54), which was predicted to most significantly affect transcription, although effect sizes varied between guide pair and guide pools (Fig. 4e, Supplementary Fig. 7D). Additionally, as an orthogonal method for Cas9 deletion, we employed CRISPR interference through a modified Suntag-system42 which enables recruitment of 10 repressive KRAB effectors at a locus through sgRNAs (Suntag-KRAB, validated in Supplementary Fig. 7A, C). Suntag-KRAB repression at the CITED2 enhancers confirms that CI54 most significantly affects transcription (Supplementary Fig. 7F), while Cas9-mediated CI54 deletion in the CITED2 expressing AR+ breast cancer cell line MDA-MB433 did not result in a transcriptional decrease, as this cell
line does not use enhancer CI54 (Supplementary Fig. 7A, G, H). These data suggest that less-frequently shared ARBS can have the largest impact on transcriptional output, which could be attributed to varying degrees of functional redundancy among ARBS.

To further confirm these findings, we focused on the AR locus, for which numerous inter-tumor heterogeneous ARBS loop to the TSS (Fig. 3a) and with confirmed AR binding and transcriptional activity in our primary patient cohort (Supplementary Fig. 8A). Using two orthogonal CRISPR drop-out screens tiling 878 sgRNAs across the entire AR enhancer region on ChrX13, AR13 (found in 13 primary tumors) proved most-critical for tumor cell proliferation, in contrast to the more-commonly shared AR23 or less-common AR2 (Fig. 4f, g).
Jointly, these data further confirm that heterogeneous ARBS can impact cellular fitness to a larger degree than more commonly shared ARBS. Interestingly, exclusively AR13 shows strong HOXB13 motif enrichment (Supplementary Fig. 5B), and HOXB13 was detected at AR13 for LNCaP and 22Rv1 cells using ChIP-seq15 (Supplementary Fig. 8C), providing a possible explanation for these observations given HOXB13’s critical nature in regulating AR-transcriptional function5.

To further investigate this, we confirmed the differential proliferation effects of AR23 and AR13 enhancer perturbation using LNCaP:Suntag-KRAB and observed similar trends in proliferation defects (Supplementary Fig. 5D, Fig. 4F, G), with AR13 perturbation having the biggest impact on cell proliferation as opposed to AR23, underlining the impact of heterogeneous ARBS on cellular fitness. Finally, we performed HOXB13 ChIP-qPCR on LNCaP:Suntag-KRAB with either NT or AR13 sgRNAs and observed that perturbation of AR13 through KRAB-mediated heterochromatinization leads to a sharp decrease of HOXB13 binding at this locus compared to NT (Supplementary Fig. 8E). These results confirm that HOXB13 binding at AR13 influences PCa cellular fitness through enhancing AR transcription.

Metastasis-associated heterogeneous ARBS in poor-outcome primary tumours drive tumor-promoting gene expression pathways

Prior studies have identified ARBS found selectively enriched in normal tissue (NARBS) over primary tumours (TARBS)3, metastasis-associated sites (met-ARBS), or those found in primary PCA7 and ARBS linked to good and poor outcomes13. As such, ARBS alterations specific to different states of PCa progression and disease outcomes have been established. With TARBS representing a general feature of primary PCa, we observe an expected TARBS enrichment for SH-ARBS, with NARBS poorly represented in our tumor samples. In contrast, met-ARBS are found mostly in heterogeneous ARBS, suggesting that heterogeneous ARBS contribute to disease progression (Fig. 5a, Supplementary Fig. 9A). In agreement with this observation, good outcome ARBS are more prevalent at SH-ARBS as compared to poor outcome ARBS (Supplementary Table 9). Our 88-patient cohort was designed as a case-control study based on biochemical recurrence (BCR)3, enabling us to independently confirm the clinical implications of AR enhancer heterogeneity. We observed a significant difference between cases and controls in good/poor outcome ARBS ratios (Fig. 5b, Supplementary Fig. 9B) ratios good/poor: (1) 1.2, good, (2) 1.2 > mixed > 0.8, (3) poor < 0.8), independently confirming poor outcome ARBS being more-heterogeneously distributed among tumors and highlighting the predictive power of these previously reported sites.

Finally, we investigated whether heterogeneous ARBS plays a role in PCa progression to metastatic disease. We observed a striking enrichment of met-ARBS at PS- and UN-ARBS over primary disease TARBS (Fig. 5c). Moreover, we separated TARBS and met-ARBS based on their presence in patients with a high chance of BCR (case) or with a low chance of BCR (control), and observed a significant enrichment of met-ARBS in cases over control patients in PS- and UN-ARBS, whereas no difference in TARBS enrichment is found in both patient populations (Fig. 5d).

We observed that met-ARBS were selectively enriched in PS- and UN-ARBS in patients whose tumors ultimately progressed. To confirm these observations on the transcriptional level, we calculated Gene Ontology Regulatory Potential (GO-RP) scores of the bottom 10% of case-specific and control-specific met-ARBS (RPscore > 0.05, Supplementary Fig. 9C, D), identifying distinct sets of genes (Fig. 5e) representing different kinds of pathways (Fig. 5f). GO-RP uses not the only distance between enhancers and promoters, but also adjusts these scores and ranks elements based on the integration of ChIP-seq and expression data to accurately identify target genes. Notably, heterogeneous case met-ARBS regulate hallmarks of cancer pathways involving cholesterol synthesis39, mTORC1 signaling40, androgen response, and WNT beta-catenin signaling41, whereas the PS3 pathway, which is often inactivated in mPCa42–44, was activated by heterogeneous control met-ARBS. Moreover, individual metastasis-promoting genes such as proto-oncogene RET45 or migration and invasiveness-related genes like CDH17, CDH18, ITGB5, and ITGB7, or osteoclast-promoting TF FOSL2 involved in the formation of bone metastases are found in this set and are regulated by heterogeneous control met-ARBS detected in cases. With comparable enrichment for TF motifs for both groups (Fig. 5g), transcriptomics data from Taylor46 and Grasso47 cohorts show that the most-heterogeneous ARBS found in primary tumors that ultimately relapse regulate genetic programs selectively altered in mPCa (Fig. 5e, h, Supplementary Fig. 9E).

Discussion

Ranging in the order of 20,000–70,000 ARBS for PCa cell lines14,17 or tumors15,17, the collection of experimentally reported ARBS is smaller compared to the total number of AR consensus motifs found throughout the human genome48. Indeed, AR chromatin binding requires a permissive epigenetic environment for AR-modulated gene expression, and reproducible epigenetic changes in PCa disease state transitions are associated with AR binding plasticity at these sites49–51. While highly recurrent state-specific alterations in AR chromatin profiles are gradually becoming established, inter-tumor heterogeneity of AR enhancer action remains largely unexplored.

We report a high level of ARBS heterogeneity between PCa primary tumors, which occurs in the same proportion in normal prostate epithelium. Such ARBS heterogeneity has biological consequences and clinical implications. First, while commonly shared ARBS are enriched for somatic mutations and exhibit AR-driven functionality, ARBS that are associated with biochemical recurrence and are thus clinically relevant were specifically acquired in metastatic disease (met-ARBS), uncommon in the patient population, and often unique to patients. As only ~30% of primary PCa patients show tumor relapse after radical prostatectomy, the majority of patients do not progress postoperatively52. In agreement with this, ARBS enriched in metastatic disease were not observed in the commonly shared fraction of primary ARBS. Second, since UN-ARBS are frequently depleted for enhancer activity in hormone-responsive LNCaP STARR-seq, heterogeneous metastasis-associated ARBS in primary PCa may lack transcription complex components essential for selective enhancer function before activation during progression, in line with our previous observations on AR plasticity in mCRPC. Third, although SNVs at ARBS rarely alter number gains (red) and loss (blue). The predominant CNA is shown, i.e. copy number gains for oncogenes occur at much higher frequencies than losses. d ARBS interacting with promoter of essential PCa genes, plotted for prevalence in patients with color denoting predominant copy number gains (red) and losses (blue) at these loci. e Metastatic PCa patient RNA-seq log2-fold expression changes over copy number neutral samples (ref call) for patients with CNAs exclusively at ARBS or exclusively at gene coding sequences. * denotes only single patient expression value in mPCa cohort, dark gray not present in mPCa cohort. Source data are provided in Source Data.
the linked gene’s expression, here we show that large-scale CNAs in mPCa affect a subset of ARBS linked to the expression of genes on which PCa cell lines are dependent. Such ARBS may not be apparent in primary PCa, but later during disease progression contribute strongly to mPCa phenotypes as illustrated by the regulation of clinically relevant genes such as RET or FOSL2 that separate primary from metastatic disease in independent patient cohorts. Finally, AR enhancer plasticity is affected by protein-coding somatic mutations, as described for FOXA1 and TMPRSS2-ERG fusions. Importantly, the resulting distinct AR chromatin interaction profiles have been linked with resistant PCa phenotypes, which switch ARBS usage under the pressure of potent AR inhibition.

Other potential underlying biological causes for ARBS heterogeneity include pioneer factor FOXA1 mutations that alter its...
cistrome\textsuperscript{65–77}, disease stage–specific epigenetic states (either induced by therapy or not)\textsuperscript{45,58} and clonal heterogeneity arising from tumor multifocality\textsuperscript{64,66}. As such, the heterogeneity of ARBS present in primary PCs could be seen as a potential pool of patient-intrinsic ARBS driving clinically relevant phenotypes by influencing transcription in later-stage disease, emphasizing the clinical impact of ARBS variations among tumors. In contrast, we observed a shift towards SH-ARBS in bicalutamide and enzalutamide-resistant PCa cell lines, underlining how currently available cell line models do not recapitulate the clinically observed ARBS heterogeneity.

Interestingly, AR enhancer chromatin accessibility varies between specific cell-cycle phases\textsuperscript{78}, and in our analysis of scATAC-seq data, which suggests that cell-cycle differences in accessibility could form another partial source of ARBS heterogeneity. Additionally, we limited our focus on ARBS that most significantly impact the expression of their target genes, while recent work shows enhancer cooperativity and mechanisms of synergism in modulating transcriptional output\textsuperscript{45}, warranting further study to dissect individual contributions of heterogeneous ARBS in enhancer-promoter landscapes. Indeed, genes are regulated by different numbers of enhancers acting at varying levels of redundancy and genomic distances, further complicating the cross-comparison of enhancer influence between individual genes.

Along similar lines, we grouped ARBS into three categories as we reasoned that SH-ARBS should occur in more than two-thirds of our cohort while UN-ARBS are defined by occurrence in a single patient. However, upon shifting the definition of SH-ARBS to occurrence in half of our cohort (n = 3113), our conclusions remain similarly statistically supported. Although we excluded false negatives and positives to the best of our abilities, some UN-ARBS could in fact be PS-ARBS or vice versa, as peaks could have been erroneously called. Importantly, such occurrences would not significantly alter our analysis of clinical consequences as this analysis is based on the lowest decile of ARBS rather than only UN-ARBS, and as such underline the robustness of conclusions drawn from categorizing ARBS. Finally, we employ machine learning to classify patient ARBS in a grouped analysis using LNCaP STARR-seq\textsuperscript{45}, which has limitations to interpretability due to contextual differences between patients, constructs, and cell lines. However, we have recently observed a strong correlation between LNCaP STARR-seq data and H3K27ac signals in patient samples\textsuperscript{51}, making such a predictive model relevant for clinical activity.

In summary, we report an immense level of AR enhancer heterogeneity in normal tissue and primary PCAs with functional consequences on gene expression during PCa progression. We provide evidence that heterogeneous ARBS are affected by somatic mutations and that CNAs acquired during PCa progression functionally contribute to malignant phenotypes to drive different gene expression programs involved in mPCA. Critically, heterogeneous AR enhancer usage in subsets of patients distinguishes patients on the outcome, indicating that epigenetic heterogeneity may be relevant in disease progression and could provide important opportunities to the field in advancing and personalizing PCa screening or treatment.

**Methods**

**Ethics statement**

No new patient samples were used in this study. The AR ChiP-seq data on 88 primary prostate cancers have been described previously\textsuperscript{5}, for which informed consent and IRB approval were given.

**Supplementary table of databases used in this study**

All GEO accession numbers and references of publicly available data used in this study are summarized in Supplementary Table 1.

**Sample collection**

All prostate tumor samples described in this study, have previously been reported and have been collected at the Department of Pathology of Portuguese Oncology Institute of Porto. Sample collection was performed in a highly standardized and optimized setup. After surgery, all radical prostatectomy samples were directly processed by the same dedicated uropathologist in a standardized manner. In brief, the whole prostate was cut transversally to the main axis into slices of ~6–7 mm thickness. Each slice was subsequently cut into quadrants and the fragment of each quadrant was halved, producing twin fragments, of which one was immediately snap-frozen and the other immediately placed in a cassette and immersed in neutral buffered formalin after which it was processed for paraffin embedding, routine histopathological assessment, and immunohistochemistry. This procedure minimized cell death and autolysis due to technical work-up, which is validated on H&E staining, as no artifacts of poor fixation were disclosed. Fragments were stained for standard neuroendocrine markers Chromogranin A and Synaptophysin and assessed for normal epithelium low expression levels (~1%). Samples were assessed for tumor cell percentage and lower tumor cell-containing samples were enriched through macro-dissection prior to cryo-sectioning to avoid significant tissue heterogeneity.

**Statistics and reproducibility**

This study is designed as 97 patients with either a high or low risk of biochemical recurrence, and whose tissues had 88 AR ChiP-seq samples passing quality control. SH-ARBS sample size was chosen as ARBS occurring in 60/88 samples, PS-ARBS sample size was chosen as all other ARBS except for ARBS occurring once in this cohort, which were defined as UN-ARBS.

**ChiP-seq ARBS calling, ranking, and data analysis**

Chromatin Immunoprecipitation sequencing data from primary tumor tissues were called using DFilter (v1.5, bs = 50, ks = 30, refine, nonzero)\textsuperscript{8} and MACS (v1.4, p-value cutoff 10e–7)\textsuperscript{8}, and only peaks identified using both algorithms were considered for further
Fig. 5 | Metastasis-associated heterogeneous ARBS in poor-outcome primary tumors drive different gene expression pathways. a Normal tissue and tumor enriched ARBS (NARBS and TARBS, respectively), primary sites, metastatic associated ARBS (met-ARBS), good and poor outcome sites presence in ranked ARBS. SH-ARBS (blue) or PS + UN-ARBS (yellow) enrichment through a two-sided hypergeometric test of enrichment, **** p < 0.0001, non-significant ns. Inset: zoom-in on outcome sites for ranked ARBS 1 through 15,000. b Distribution of ratio of outcome sites per primary PCa patient split for BCR development (case) or not (control). Ratios good:poor; (1) >1.2 good (blue), (2) 1.2 > mixed > 0.8 (purple), (3) poor < 0.8 (red). Two-sided Fisher's exact test, *p < 0.05. c Distribution of TARBS (T, red dotted line) and Met-ARBS (M, purple line) in ranked ARBS. Centerline, median; upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers. Two-tailed Student’s t-test of means, **** p < 0.0001 d Histograms of TARBS (red) or Met-ARBS (purple) counted in patients, split for BCR development (case) or not (control). Two-sided Kolmogorov–Smirnov test of distribution, **** p < 0.0001. e Euler diagram of a number of genes with GO regulatory potential score >0.5 for met-ARBS which are specific for primary patients with biochemical recurrence (BCR) development (case) or without (control). Students’ t-test analysis (GSEA) for hallmarks of cancer using GO RP score >0.05, for genes linked to case-(left) and control-specific (right) met-ARBS in less than 10% of patients. g Transcription factor motif analysis of case/control specific met-ARBS with motif z-scores. h Heatmap clustering (k = 2) for Taylor (FDR < 0.01) and Grasso cohort z-score expression levels from patient tissues filtered for case-specific met-ARBS genes <10% of patients. Source data are provided in Source Data.
downstream analyses after extensive quality control. All reported genomic locations in this study are in GrCh37/hg19 and when required for analysis were lifted over from GRCh38/hg38 using ucsc-liftOver (v366) command-line and hg38ToHg19.over.chain file. Transcriptional Start Sites (TSS) including promoter regions were removed by excluding 1000 bp from all gene TSS in all patient ARBS peaklists using BEDtools (v2.29).93 ARBS peaklists were then intersected and peak occurrence in the total population was counted using BEDtools. Tumor ARBS were ranked for patient occurrence, then for genomic location, and subsequently used to intersect with other databases (Source Data) using BEDtools and plotted for the co-occurrence of ARBS in both sets in a heatmap by R package NMF(v0.23.0).94 ARBS were grouped into three categories based on ARBS prevalence in the entire cohort, with SH-ARBS defined as occurring in 60 or more patients (68% of patients), PS-ARBS defined as occurring in 2–59 patients (267% of patients) and UN-ARBS defined as occurring in only one patient. Normal prostate epithelium ARBS peaklists were pooled from two databases and processed similarly and the tumor and normal ARBS rankings were normalized by patients for comparison (Supplementary Table 6). Differences in the spread between normal and tumor ARBS ranking in cell lines were statistically compared using two-tailed Student’s t-test of means. Enrichment of ARBS in ranked ARBS groups was calculated using hypergeometric test with P(O>x) condition.

Tumor-ranked ARBS consensus were generated sequentially with minimal ARBS overlap starting at peaks found in 88 patients and then found in one less patient for each consensus using DiffBind (v3.4.9) and resulting genomic regions were annotated using ChiPpeakAnno(v3.28.0).95. Genomic peak snapshots were taken using IGV-Web(v1.6.3)96. ARBS ChiP-seq tandem plots and aggregate genomic ChiP-seq signal plots were generated using Easeq(v1.03).97. Bams around ARBS genomic locations were gated for ARBS categories and normalized across the genome. Multiple testing corrections and quality control of ranked ARBS as true-positives were performed using MSCP(v5.4.0)98 with default settings. TF binding overlap of ranked ARBS per category with publicly available ChiP-seq data from ENCODE, Roadmap Epigenomics, and GTEx was performed using transcription factor GIGGLE (http://abantoolkit.cistrome.org/).99. Ranked ARBS were analyzed for TF motifs using Cistrome SeqPos and screened for AR, FOXA1, or HOXB3 motif presence using Cistrome MISP and the validity of results was checked through independently running MEME-MAST on ARBS with standard settings. Permutation tests of equality on density distributions were performed using R package sm. density.compare with model assumption = equal, n = 1000 permutations with ngrid = 100 for plotting estimates.

Cell culture
LNCaP cells (ATCC, CRL-1740) were grown in RPMI medium (Gibco) with 10% fetal bovine serum and 1% penicillin–streptomycin (PS). HEK cells (ATCC, CRL-3216) were grown in DMEM medium (Gibco) with 10% fetal bovine serum and 1% penicillin–streptomycin. LNCaP and HEK cells were dissociated with 0.05% trypsin solution. For experiments in different hormonal conditions, cells were cultured for 3 days in RPMI medium containing 5% dextran-coated charcoal (DCC)-stripped FBS and 1% PS. The medium was replaced with RPMI medium containing 5% charcoal-stripped FBS, 1% PS, and 10 nM synthetic androgen R1881 or an equal amount of DMSO. After 4 h in the R1881-containing medium, cells were harvested for simultaneous total RNA and gDNA isolation. All cell lines have been authenticated through STR profiling and were regularly found to test negative for mycoplasma contamination.

STARR-seq and luciferase validation
STARR-seq was performed and analyzed for EtOH or DHT-stimulated LNCaP cells, which were electroporated using a library focused on common clinical ARBS (NARBS and TARBS). Machine learning of ARBS activity was performed, excluding predicted inactive sites while intersecting predicted constitutively active and predicted inducible ARBS with ranked ARBS using BEDtools. Additional STARR-seq sites were designed in an unbiased manner among the entire ranked ARBS universe by randomly sampling ARBS, resulting in a library of STARR-seq constructs containing more homogeneously spread ARBS throughout the ranking than our previous targeted NARB and TARB library. Additional STARR-seq ARBS were electroporated in LNCaP and treated with either EtOH or 10 nM DHT for 4 h and harvested 72 h post electroporation. To determine additional ARBS with STARR activity we first downsampld 2 replicate LNCaP vehicle (ethanol) STARR-seq files to equivalent read counts and merged them into one file with samtools (v1.3). Kmeans clustering was carried out using deepTools (v2.0) bamCoverage, computeMatrix, and plotHeatmap functions. Those ARBS with signals in the top 1 and 2 of 3 clusters were considered active (n = 149). All other ARBS found in cluster 3 were considered inactive (n = 2346).

For performing luciferase assays, regions of interest were PCR amplified from pooled male human genomic DNA (Promega) with overhangs added for Gibson assembly. The amplified regions were then cloned into a modified STARR luciferase validation vector ORI empty plasmid (Addgene #99298) using the NEBuilder HiFI DNA Assembly master mix (NEB). Primers used to amplify the regions are described in Supplementary Data 1. All insert sequences were verified by Sanger sequencing using Primers 1 and 4 (Supplementary Table 1). For data analysis, technical triplicates were averaged. A two-tailed Student’s t-test was performed (R package v.2.28.0), with significance levels defined as a p-value < 0.05. Expression of AR ChIP-seq sample, of which >95% are regarded as active, was calculated using hypergeometric test with P(O>x) condition.

Somatic mutations, mutation rate, and super-enhancers
Publicly available rSNP (Supplementary Table 1) primary and metastatic prostate cancer SNV data (Supplementary Table 1, Source Data) was downloaded and intersected with ranked ARBS using BEDtools. Observed over background mutation rate in the whole genome was calculated and statistically compared to mutation rates in ARBS using Fisher’s exact test. Super-enhancer genomic location data was downloaded from SEDb and dBSUPER for prostate cancer cell lines and tissues and intersected with ranked ARBS using BEDtools. Additional cQTL rSNP data was inferred from allelic imbalance observed in AR ChIP-seq sample, of which p-values were adjusted using R package qvalue (v2.28.0), with significant imbalance called when peaks contained one or more SNPs at q < 0.05.

Genomic interaction data handling, CNA data partitioning, and gene dependency data
H3K27ac HiChIP sequencing regions from LNCaP cells were downloaded and filtered for promoter-enhancer (PE) or enhancer–promoter (EP) interactions. Filtered anchors were intersected with ranked tumor ARBS using BEDtools. Copy Number Alteration and normalized RNA-seq data from 101 metastatic PCa patients were downloaded, with
Co-accessibility analysis was performed using Cicero(v1.12.0) and monocle3(v1.11.0)\(^8\),\(^9\). The distance parameter was estimated using a distance constraint of 2.5 Mb with a window size of 5 Mb. Cicero models were constructed, connections assembled, and the cis-co-accessibility networks were generated at a cutoff of 0.1. Midpoints of the connected elements identified by cicero were linked and links with score > 0.05 were filtered out.

Oligonucleotides

Supplementary Data 1 gives an overview of all used oligonucleotides.

sgRNA design and production

Guide RNAs for CRISPR/Cas9 deletion was designed to closely flank ARBS of interest and maximize both MIT and Doench scores for optimal guide efficiency during mammalian lentiviral transduction. Guides were annealed and cloned in lentiguide-puro plasmid (Addgene, 52963)\(^8\),\(^9\). All sgRNA lentiguide-puro sequences were Sanger sequences verified using U6-forward primer. sgRNA pairs and pools for CRISPR/Cas9 ARBS deletion were pooled equimolarly prior to outgrowth, as confirmed by PCR with U6-F primer and a corresponding reverse sgRNA oligo (Supplementary Data 1, detailed protocol available at https://portals.broadinstitute.org/gpp/public/resources/protocols).

CRISPR-Cas9 deletion

LNCaP cells were infected with a lentivirus encoding Cas9-eGFP (Addgene, 63392) and GFP-positive cells were flow cytometry selected, after which presence of Cas9 in GFP+ cells was confirmed by western blot with antibodies Cas9 (Cell Signaling #14697, clone 7A9-3A3, diluted 1:1000, positive cell line included) and actin (Sigma Aldrich A2228, clone C4, diluted 1:1000). Cas9 activity was confirmed by lentivirally infecting GFP-Cas9+ cells with a GFP promoter-targeting sgRNA pair after which cells were analyzed on a flow cytometer. sgRNA-containing lentiviruses were produced by transfecting HEK 293T cells (6.5 × 10^7 cells/100 mm plate, 60–70% confluency) with a mix of psPAX2 (Addgene, #12260), pmD2.G (Addgene, #12259), sgRNA containing lentiguide-puro and PEI (PEI/DNA ratio 3:1). Cells were transfected in warm oMEM medium without FCS or PS (Gibco). Medium was supplemented with DMEM (10% FCS, 1% PS) 3 h post-transfection and incubated overnight, after which medium was refreshed with DMEM (10% FCS, 1% PS). Two days post-transfection, the virus-containing medium was harvested by filtering through a 0.45 μm filter and immediately used to infect 2.0 × 10^5 GFP-Cas9+ LNCaP cells/six-well plate in RPMI (10% FCS, 1% PS) containing polybrene (10 μg/ml). After two days, cells were selected with puromycin (2 μg/ml). Afterward, the selection was maintained continuously at 1 μg/ml puromycin during culture for 30–40 days until harvest. AR breast cancer cell line MDA-MB433 (ATCC HTB-131) was cultured in a similar manner as LNCaP and infected with Cas9-eGFP lentivirus as described above.

gDNA/RNA isolation, cDNA synthesis for qPCR and PCR verification of CRISPR-Cas9 deletion

Genomic DNA and RNA were isolated from cells washed in ice-cold PBS and resuspended in 0.75 ml TRIzol LS reagent per the manufacturer’s instructions (Invitrogen, 15936026). gDNA was precipitated with 100% ethanol, and washed twice with 0.1 M sodium citrate in 10% ethanol, after which gDNA solubilization was facilitated by DNA hydration solution (Qiagen, IS445). RNA was precipitated with isopropanol and the resulting RNA pellet was washed in 75% ethanol and resuspended in nuclease-free water for immediate use in cDNA synthesis or stored at −80 °C for later use.

To generate first-strand cDNA, 2500 ng RNA was primed with 5pM oligo(dT) and 10 mM dNTP mix. cDNA was synthesized as per SuperScript III first-strand synthesis per the manufacturer’s instructions
CRISPR interference of CITED2 in LNCaP:Suntag-KRAB

The existing Suntag-VP64 construct (pHRdsV40-scFv-GCN4-sfGFP-VP64-GBI-NLS; Addgene, #60904) was adapted by swapping the activating effector VP64 for the repressing KRAB effector using Gibson Assembly and Rsrl (Thermo Fisher). Briefly, KRAB was amplified from pLX_31H-KRAB-dCas9 (Addgene, #96918) using PCR primers with homology arms that were specifically designed to keep the original scFv-GCN4-sfGFP-effector-GBI-NLS linker architecture intact (Supplementary Data 1). LNCaP cells were subsequently infected with lentivirus containing LNCaP conditioned medium for monoclonal selection using BN20 (Santa Cruz Biotechnology; sc-66923 clone H-80) was used per condition with 50 μl Protein A Dynabeads (Invitrogen). After ChIP completion, qPCR was performed using specific and specific site primers (SI negative and AR13-q95, respectively) on 1.5: diluted solution from 50 μl of dissolved DNA pellet.

State-specific sites in ranked ARBS and good/poor outcome predictor

ARBS collections identified in earlier studies spanning PCA disease state transitions and association with outcome were downloaded and intersected with ranked ARBS using BEDtools. Primary PCA patient ARBS peaklists were divided in groups of patients with (cases) or without (controls) BCR development. For each group, patients were divided in three groups based on the proportion of good to bad outcome sites in which (1) >1.2 good, (2) 1.2 > mixed > 0.8, (3) poor < 0.8 and used Fisher's exact test for statistical analysis. TARBS and met-ARBS in ranked ARBS were counted for each individual patient inside the case and control groups and plotted in histograms detailing the total ARBS for each group per ranked ARBS occurrence. Statistical difference between histograms was calculated using two-sided Kolmogorov–Smirnov test.

GO regulatory potential of Met-ARBS, Gene Set Enrichment Analysis, Heatmap clustering

Regulatory Potential scores for genes were calculated using regions peak files for met-ARBS found in 8 or fewer primary patients that developed a BCR recurrence versus those without as input for Cistrome-GO and filtered for genes with RPScore > 0.05. Genes were analyzed for ranked pathway analysis using GSEA(4.1.0) and MSigDB(7.3, hallv7.0. symbols.gmt Hallmarks). Met-ARBS genes in 8 or fewer patients were used to filter publicly available and clinically annotated PCA expression data from Taylor(109) and Grasso cohorts. Taylor count data was normalized using DESeq2 and differentially expressed genes with FDR < 0.01 were used. Grasso mean ±scores for differentially expressed genes were used. Heatmaps for gene expression were plotted using ComplexHeatmap with optimal kclustermeans determined from Silhouette plots generated by R package factoextra (v1.0.7, https://rpkgs.datanovia.com/factoextra/index.html) using Euclidian distance metric.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data are available within the article, Supplementary information and Source data file. Source data are provided with this paper. Public datasets are available through GSE accession numbers as reported in Supplementary Table 1 and additional STARR-seq data is deposited at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217319 or accessible through GSEA accession number GSE217319. Source data are provided with this paper.

Code availability

Code is available through https://github.com/jknpr/arbshet.

References

1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209–249 (2021).
2. Stelloo, S., Bergman, A. M. & Zwart, W. Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers. Endocr. Relat. Cancer 26, R267–R285 (2019).
3. Stelloo, S. et al. Integrative epigenetic taxonomy of primary prostate cancer. Nat. Commun. 9, 1–12 (2018).
4. Pomerantz, M. M. et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat. Genet. 47, 1346–1351 (2015).
5. Pomerantz, M. M. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat. Genet. 52, 790–799 (2020).
6. Baca, S. C. et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat. Commun. 12, 1979 (2021).

7. Severson, T. M. et al. Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases. Mol. Oncol. 15, 1942–1955 (2021).

8. Stelloo, S. et al. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol. Med. 7, 1450–1464 (2015).

9. Jiang, Y. et al. S6dB: a comprehensive human super-enhancer database. Nucleic Acids Res. 47, D235–D243 (2019).

10. Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364 (2017).

11. Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758–769 (2018).

12. Huang, C.-C. F. et al. Functional mapping of androgen receptor enhancer activity. Genome Biol. 22, 149 (2021).

13. Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell 174, 422–432 (2018).

14. Taavitsainen, S. et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat. Commun. 12, 5307 (2021).

15. Kron, K. J. et al. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat. Genet. 49, 1336–1345 (2017).

16. Takayama, K. et al. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat. Commun. 6, 8219 (2015).

17. Toropainen, S. et al. Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets. Sci. Rep. 6, 33510 (2016).

18. Cioni, B. et al. Androgen receptor signalling in macrophages promotes TREM1-mediated prostate cancer cell line migration and invasion. Nat. Commun. 11, 4498 (2020).

19. Malinen, M. et al. Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells. Mol. Cell. Endocrinol. 414, 91–98 (2015).

20. Landt, S. G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 22, 1813–1831 (2012).

21. Chen, Z. et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 34, 502–516 (2015).

22. Hoffman, M. M. et al. Integrative annotation of chromatin elements from ENCODE data. Nucleic Acids Res. 41, 827–841 (2013).

23. Jin, H.-J., Zhao, J. C., Wu, L., Kim, J. & Yu, J. Coopetivity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat. Commun. 5, 3972 (2014).

24. Layer, R. M. et al. GIGGLE: a search engine for large-scale integrated genome analysis. Nat. Methods 15, 123–126 (2018).

25. Arnold, C. D. et al. Genome-Wide Quantitative Enhancer Activity Maps Identified by STARR-seq. Science 339, 1074–1077 (2013).

26. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001–D1006 (2014).

27. Hazelett, D. J. et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 10, e1004102 (2014).

28. Chen, H. et al. Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci. Prostate 75, 1264–1276 (2015).

29. Baca, S. C. et al. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nat. Genet. 54, 1364–1375 (2022).

30. Morova, T. et al. Androgen receptor-binding sites are highly mutated in prostate cancer. Nat. Commun. 11, 832 (2020).

31. Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).

32. Lovén, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).

33. Mazrooei, P. et al. Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors. Cancer Cell 36, 674–689.e6 (2019).

34. Wang, X. et al. Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis. 23, 494–506 (2020).

35. Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433–447 (2018).

36. Stelloo, S. et al. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. Oncogene 37, 313–322 (2018).

37. Giambartolomei, C. et al. H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility. Am. J. Hum. Genet. 108, 2284–2300 (2021).

38. Zhang, Z. et al. An AR-ERG transcriptional signature defined by long range chromatin interactomes in prostate cancer cells. Genome Res. https://doi.org/10.1101/gr.230243.117 (2019).

39. Fisheriak, A. et al. Defining a cancer dependency map. Cell 170, 564–576.e16 (2017).

40. Paltoglou, S. et al. Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer. Cancer Res. 77, 3417–3430 (2017).

41. McNair, C. et al. Cell-cycle coupled expansion of AR activity promotes cancer progression. Oncogene 36, 1655 (2017).

42. Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S. & Vale, R. D. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635–646 (2014).

43. Stopsack, K. H. et al. Aneuploidy drives lethal progression in prostate cancer. Proc. Natl Acad. Sci. USA 116, 11390–11395 (2019).

44. Shorning, B. Y., Dass, M. S., Smally, M. J. & Pearson, H. B. The P3KAKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT Signaling. Int. J. Mol. Sci. 21, 4507 (2020).

45. Nientiedt, C. et al. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer—results from a prospective pilot study using a 37 gene panel. Urol. Oncol. Semin. Orig. Invest. 38, 637.e1–637.e27 (2020).

46. VanDeusen, H. R. et al. Targeting RET Kinase in Neuroendocrine Prostate Cancer. Mol. Cancer Res. 18, 1176–1188 (2020).

47. Tang, F. et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science 376, eabe1505 (2022).

48. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).

49. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

50. Wilson, S., Qi, J. & Filipp, F. V. Recruitment of TREM-1-mediated prostate cancer cell line migration by STARR-seq. Nat Commun. 75, 1364 (2016).

51. Antonarakis, E. S. et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 109, 32–39 (2012).

52. Zhou, S. et al. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nat. Commun. 11, 441 (2020).

53. Li, F. et al. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. J. Clin. Invest. 130, 5924–5941 (2020).
54. Davies, A. et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat. Cell Biol. 23, 1023–1034 (2021).
55. Adams, E. J. et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571, 408–412 (2019).
56. Parolia, A. et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 1, https://doi.org/10.1038/s41586-019-1347-4 (2019).
57. Gao, S. et al. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res. 29, 770 (2019).
58. Nouri, M. et al. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget 8, 18349–18367 (2017).
59. Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736–745 (2015).
60. Kneppers, J. et al. Frequent clonal relations between metastasis and non-index prostate cancer lesions. JCI Insight 4, e124756 (2019).
61. Choi, J. et al. Evidence for additive and synergistic action of mammalian enhancers during cell fate determination. eLife 10, e65381 (2021).
62. Linder, S. et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence. Cancer Discov. candisc.0576.2021.5-3 12:14.4731 https://doi.org/10.1158/2159-8290.CD-21-0576 (2022).
63. Kumar, V. et al. Uniform, optimal signal processing of mapped deep-sequencing data. Nat. Biotechnol. 31, 615–622 (2013).
64. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
65. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
66. Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinform. 11, 367 (2010).
67. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389–393 (2012).
68. Zhu, L. J. et al. ChiPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinform. 11, 237 (2010).
69. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
70. Lerdrup, M., Johansen, J. V., Agrawal-Singh, S. & Hansen, K. An interactive environment for agile analysis and visualization of ChIP-sequencing data. Nat. Struct. Mol. Biol. 23, 349–357 (2016).
71. Jalili, V., Matteucci, M., Masseroli, M. & Morelli, M. J. Using combined evidence from replicates to evaluate ChIP-seq peaks. Bioinformatics 31, 2761–2769 (2015).
72. Liu, T. et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 12, R83 (2011).
73. Wang, S. et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat. Protoc. 8, 2502–2515 (2013).
74. Bailey, T. L. & Gribskov, M. Combining evidence using p-values: application to sequence homology searches. Bioinformatics 14, 48–54 (1998).
75. Bowman, A. W. & Azzalini, A. Applied Smoothing Techniques for Data Analysis: The Kernel Approach with S-Plus Illustrations (OUP Oxford, 1997).
76. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinforma. Oxf. 25, 2078–2079 (2009).
77. Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
78. Zhang, P. et al. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat. Commun. 9, 1–12 (2018).
79. Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936 (2018).
80. De Ryckye, M. S. et al. An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set. PLoS ONE 14, e0214588 (2019).
81. Khan, A. & Zhang, X. dbSUPER: a database of super-enhancers in mouse and human genome. Nucleic Acids Res. 44, D164–D171 (2016).
82. Lawrence, M. et al. Software for computing and annotating genomic ranges. PLoS Comput. Biol. 9, e1003118 (2013).
83. Yu, C. et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat. Biotechnol. 34, 419–423 (2016).
84. Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
85. Werft, W. & Benner, A. glmperm: a permutation of regressor residuals test for inference in generalized linear models. R. J. 2, 39 (2010).
86. Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).
87. Stuart, T., Srivastava, A., Madad, S., Lareau, C. A. & Satija, R. Single-cell chromatin state analysis with Signac. Nat. Methods 18, 1333–1341 (2021).
88. Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. Chromium: inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nat. Methods 14, 975–978 (2017).
89. Gel, B. et al. regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. Bioinformatics 32, 289–291 (2016).
90. Pliner, H. A. et al. Cicero predicts cis-regulatory DNA interactions from single-cell chromatin accessibility data. Mol. Cell 71, 858–871.e8 (2018).
91. Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).
92. Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979–982 (2017).
93. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783 (2014).
94. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
95. Gregorichio, S. et al. HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroblasts. Nucleic Acids Res. 50, 7938–7958 (2022).
96. Li, S. et al. Cistrome-GO: a web server for functional enrichment analysis of transcription factor ChIP-seq peaks. Nucleic Acids Res. 47, W206–W211 (2019).
97. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
98. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417 (2015).
99. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
100. Gu, Z., Els, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinforma. Oxf. 32, 2847–2849 (2016).
Acknowledgements
We would like to acknowledge the NKI Genomics Core Facility for Illumina sequencing and bioinformatics support and the NKI Research High-Performance Computing (RHPC) facility for computational infrastructure. We express gratitude to all members of the Zwart and Bergman lab, and members of the NKI Oncogenomics division for helpful scientific discussion. This work was supported by the Prostate Cancer Foundation (21HAL04), Department of Defense (W81XWH-21-1-0234, W81XWH-19-1-0565), Oncode Institute and Alpe d’HuZes/KWF Dutch Cancer Society (10084).

Author contributions
J.K., S.E.P.J., A.M.B., and W.Z. conceptualized the study. J.K., P.S. I.P.L.Y., and C.F.H. performed experiments. J.K., T.S., and J.C.S. performed computational analyses. I.P.L.Y. and C.F.H. performed STARR-seq experiments and J.K., T.S., T.M., U.B.A., and N.A.L. performed STARR-seq analyses. I.C., C.J., and R.H. collected and processed tissue samples for pathology. C.G., J.C.S., C.G., J.H.S., S.C.B., E.E., B.P., M.L.F., L.F.A.W., and N.A.L. provided dataset resources. J.K., A.M.B., and W.Z. wrote the original draft manuscript. J.K., T.S., J.C.S., S.E.P.J., I.P.L.Y., C.G., R.H., N.A.L., A.M.B., and W.Z. reviewed and edited the manuscript with input from all co-authors. J.K., A.M.B., and W.Z. supervised the study.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-35135-2.

Correspondence and requests for materials should be addressed to Andries M. Bergman or Wilbert Zwart.

Peer review information Nature Communications thanks Matti Nykter, Ping Mu, Suhn Rhie and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

1Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands. 2Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands. 3Vancouver Prostate Centre, Department of Urologic Science, University of British Columbia, Vancouver, Canada. 4School of Medicine, Koç University, Istanbul, Turkey. 5Central RNA Lab, Istituto Italiano di Tecnologia, Genova, Italy. 6Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA. 7The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, USA. 8Department of Pathology, Cancer Biology and Epigenetics Group, Portuguese Oncology Institute of Porto and Porto Comprehensive Cancer Center, Porto, Portugal. 9Department of Physics, Simon Fraser University, Burnaby, Canada. 10Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, USA. 11Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey. 12Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 13Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. E-mail: a.bergman@nki.nl; w.zwart@nki.nl.